Lipocine (NASDAQ:LPCN) Lifted to “Buy” at StockNews.com

StockNews.com upgraded shares of Lipocine (NASDAQ:LPCN) from a hold rating to a buy rating in a research report released on Monday morning.

Separately, Alliance Global Partners initiated coverage on shares of Lipocine in a research note on Tuesday, September 24th. They set a “buy” rating and a $10.00 price objective for the company.

Lipocine Price Performance

Shares of LPCN opened at $5.08 on Monday. The stock has a market cap of $27.17 million, a P/E ratio of -2.97 and a beta of 1.22. The business’s 50 day moving average price is $4.27 and its 200-day moving average price is $5.59. Lipocine has a 52 week low of $2.31 and a 52 week high of $11.79.

Lipocine (NASDAQ:LPCN) last released its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.56) EPS for the quarter. The business had revenue of $0.09 million during the quarter. On average, equities analysts anticipate that Lipocine will post -0.92 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new position in Lipocine Inc. (NASDAQ:LPCN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned about 0.22% of Lipocine at the end of the most recent reporting period. 9.11% of the stock is currently owned by institutional investors and hedge funds.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.